TELADOC HEALTH INC (TDOC) Fundamental Analysis & Valuation

NYSE:TDOC • US87918A1051

Current stock price

5.75 USD
+0.05 (+0.88%)
At close:
5.69 USD
-0.06 (-1.04%)
After Hours:

This TDOC fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

3

1. TDOC Profitability Analysis

1.1 Basic Checks

  • In the past year TDOC has reported negative net income.
  • TDOC had a positive operating cash flow in the past year.
  • In the past 5 years TDOC always reported negative net income.
  • TDOC had a positive operating cash flow in each of the past 5 years.
TDOC Yearly Net Income VS EBIT VS OCF VS FCFTDOC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -5B -10B

1.2 Ratios

  • TDOC has a Return On Assets of -7.01%. This is comparable to the rest of the industry: TDOC outperforms 57.14% of its industry peers.
  • TDOC has a Return On Equity of -14.46%. This is comparable to the rest of the industry: TDOC outperforms 60.00% of its industry peers.
Industry RankSector Rank
ROA -7.01%
ROE -14.46%
ROIC N/A
ROA(3y)-13.5%
ROA(5y)-71.46%
ROE(3y)-30.36%
ROE(5y)-137.12%
ROIC(3y)N/A
ROIC(5y)N/A
TDOC Yearly ROA, ROE, ROICTDOC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -100 -200 -300 -400 -500

1.3 Margins

  • TDOC has a better Gross Margin (69.50%) than 71.43% of its industry peers.
  • TDOC's Gross Margin has improved in the last couple of years.
  • The Profit Margin and Operating Margin are not available for TDOC so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 69.5%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.2%
GM growth 5Y1.58%
TDOC Yearly Profit, Operating, Gross MarginsTDOC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -200 -400

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. TDOC Health Analysis

2.1 Basic Checks

  • TDOC does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, TDOC has more shares outstanding
  • TDOC has more shares outstanding than it did 5 years ago.
  • Compared to 1 year ago, TDOC has an improved debt to assets ratio.
TDOC Yearly Shares OutstandingTDOC Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M
TDOC Yearly Total Debt VS Total AssetsTDOC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5B 10B 15B

2.2 Solvency

  • Based on the Altman-Z score of -6.63, we must say that TDOC is in the distress zone and has some risk of bankruptcy.
  • TDOC has a worse Altman-Z score (-6.63) than 82.86% of its industry peers.
  • TDOC has a debt to FCF ratio of 7.24. This is a slightly negative value and a sign of low solvency as TDOC would need 7.24 years to pay back of all of its debts.
  • Looking at the Debt to FCF ratio, with a value of 7.24, TDOC is in line with its industry, outperforming 60.00% of the companies in the same industry.
  • A Debt/Equity ratio of 0.72 indicates that TDOC is somewhat dependend on debt financing.
  • TDOC has a worse Debt to Equity ratio (0.72) than 80.00% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.72
Debt/FCF 7.24
Altman-Z -6.63
ROIC/WACCN/A
WACC6.59%
TDOC Yearly LT Debt VS Equity VS FCFTDOC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5B 10B 15B

2.3 Liquidity

  • TDOC has a Current Ratio of 2.77. This indicates that TDOC is financially healthy and has no problem in meeting its short term obligations.
  • With a decent Current ratio value of 2.77, TDOC is doing good in the industry, outperforming 68.57% of the companies in the same industry.
  • TDOC has a Quick Ratio of 2.67. This indicates that TDOC is financially healthy and has no problem in meeting its short term obligations.
  • TDOC's Quick ratio of 2.67 is fine compared to the rest of the industry. TDOC outperforms 62.86% of its industry peers.
Industry RankSector Rank
Current Ratio 2.77
Quick Ratio 2.67
TDOC Yearly Current Assets VS Current LiabilitesTDOC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. TDOC Growth Analysis

3.1 Past

  • TDOC shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 8.06%, which is quite good.
  • TDOC shows a decrease in Revenue. In the last year, the revenue decreased by -1.54%.
  • TDOC shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 18.26% yearly.
EPS 1Y (TTM)8.06%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%50%
Revenue 1Y (TTM)-1.54%
Revenue growth 3Y1.68%
Revenue growth 5Y18.26%
Sales Q2Q%0.28%

3.2 Future

  • The Earnings Per Share is expected to grow by 10.91% on average over the next years. This is quite good.
  • The Revenue is expected to grow by 3.45% on average over the next years.
EPS Next Y23.41%
EPS Next 2Y16.16%
EPS Next 3Y12.8%
EPS Next 5Y10.91%
Revenue Next Year-0.51%
Revenue Next 2Y0.37%
Revenue Next 3Y0.73%
Revenue Next 5Y3.45%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
TDOC Yearly Revenue VS EstimatesTDOC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 1B 2B 3B
TDOC Yearly EPS VS EstimatesTDOC Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 -10 -20 -30 -40 -50

More info and screens

Find the best growth stocksShow best growing peers

3

4. TDOC Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for TDOC. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for TDOC. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TDOC Price Earnings VS Forward Price EarningsTDOC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, TDOC is valued cheaper than 91.43% of the companies in the same industry.
  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of TDOC indicates a rather cheap valuation: TDOC is cheaper than 91.43% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 7.55
EV/EBITDA 6.19
TDOC Per share dataTDOC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10

4.3 Compensation for Growth

  • A more expensive valuation may be justified as TDOC's earnings are expected to grow with 12.80% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y16.16%
EPS Next 3Y12.8%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. TDOC Dividend Analysis

5.1 Amount

  • TDOC does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

TDOC Fundamentals: All Metrics, Ratios and Statistics

TELADOC HEALTH INC

NYSE:TDOC (4/24/2026, 8:10:34 PM)

After market: 5.69 -0.06 (-1.04%)

5.75

+0.05 (+0.88%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)02-25
Earnings (Next)04-29
Inst Owners75.4%
Inst Owner Change0.5%
Ins Owners0.58%
Ins Owner Change1.8%
Market Cap1.04B
Revenue(TTM)2.53B
Net Income(TTM)-200.32M
Analysts69.7
Price Target7.09 (23.3%)
Short Float %17.69%
Short Ratio5.15
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)11.85%
Min EPS beat(2)-3.18%
Max EPS beat(2)26.88%
EPS beat(4)2
Avg EPS beat(4)-0.46%
Min EPS beat(4)-54.19%
Max EPS beat(4)28.67%
EPS beat(8)4
Avg EPS beat(8)4.17%
EPS beat(12)8
Avg EPS beat(12)7.08%
EPS beat(16)10
Avg EPS beat(16)-744.49%
Revenue beat(2)0
Avg Revenue beat(2)-1.38%
Min Revenue beat(2)-1.88%
Max Revenue beat(2)-0.88%
Revenue beat(4)0
Avg Revenue beat(4)-0.9%
Min Revenue beat(4)-1.88%
Max Revenue beat(4)-0.35%
Revenue beat(8)0
Avg Revenue beat(8)-1.2%
Revenue beat(12)0
Avg Revenue beat(12)-1.45%
Revenue beat(16)0
Avg Revenue beat(16)-1.47%
PT rev (1m)-20.16%
PT rev (3m)-22.55%
EPS NQ rev (1m)-0.41%
EPS NQ rev (3m)-28.53%
EPS NY rev (1m)1.17%
EPS NY rev (3m)-11.39%
Revenue NQ rev (1m)-0.11%
Revenue NQ rev (3m)-3.23%
Revenue NY rev (1m)-0.08%
Revenue NY rev (3m)-1.5%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.41
P/FCF 7.55
P/OCF 3.52
P/B 0.75
P/tB N/A
EV/EBITDA 6.19
EPS(TTM)-1.14
EYN/A
EPS(NY)-0.87
Fwd EYN/A
FCF(TTM)0.76
FCFY13.24%
OCF(TTM)1.63
OCFY28.37%
SpS14.02
BVpS7.68
TBVpS-1.08
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -7.01%
ROE -14.46%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 69.5%
FCFM 5.43%
ROA(3y)-13.5%
ROA(5y)-71.46%
ROE(3y)-30.36%
ROE(5y)-137.12%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.2%
GM growth 5Y1.58%
F-Score5
Asset Turnover0.89
Health
Industry RankSector Rank
Debt/Equity 0.72
Debt/FCF 7.24
Debt/EBITDA 4.96
Cap/Depr 43.13%
Cap/Sales 6.21%
Interest Coverage N/A
Cash Conversion 146.68%
Profit Quality N/A
Current Ratio 2.77
Quick Ratio 2.67
Altman-Z -6.63
F-Score5
WACC6.59%
ROIC/WACCN/A
Cap/Depr(3y)40.79%
Cap/Depr(5y)44.08%
Cap/Sales(3y)5.68%
Cap/Sales(5y)5.47%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)8.06%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%50%
EPS Next Y23.41%
EPS Next 2Y16.16%
EPS Next 3Y12.8%
EPS Next 5Y10.91%
Revenue 1Y (TTM)-1.54%
Revenue growth 3Y1.68%
Revenue growth 5Y18.26%
Sales Q2Q%0.28%
Revenue Next Year-0.51%
Revenue Next 2Y0.37%
Revenue Next 3Y0.73%
Revenue Next 5Y3.45%
EBIT growth 1Y21.51%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year213.84%
EBIT Next 3Y48.15%
EBIT Next 5Y28.54%
FCF growth 1Y-19.04%
FCF growth 3Y102.66%
FCF growth 5YN/A
OCF growth 1Y0.23%
OCF growth 3Y15.85%
OCF growth 5YN/A

TELADOC HEALTH INC / TDOC Fundamental Analysis FAQ

What is the ChartMill fundamental rating of TELADOC HEALTH INC (TDOC) stock?

ChartMill assigns a fundamental rating of 3 / 10 to TDOC.


Can you provide the valuation status for TELADOC HEALTH INC?

ChartMill assigns a valuation rating of 3 / 10 to TELADOC HEALTH INC (TDOC). This can be considered as Overvalued.


What is the profitability of TDOC stock?

TELADOC HEALTH INC (TDOC) has a profitability rating of 3 / 10.


What is the expected EPS growth for TELADOC HEALTH INC (TDOC) stock?

The Earnings per Share (EPS) of TELADOC HEALTH INC (TDOC) is expected to grow by 23.41% in the next year.